永安藥業(002365.SZ):擬投2.5億元擴建年產4萬噸牛磺酸食品添加劑項目
格隆匯12月2日丨永安藥業(002365.SZ)公佈,公司第六屆董事會第四次會議審議通過了《關於擴建年產4萬噸牛磺酸食品添加劑項目的議案》,同意公司使用自有資金2.5億元人民幣擴建年產4萬噸牛磺酸食品添加劑項目。
建設規模:公司擬在湖北省潛江經濟開發區廣澤大道2號現有廠區內,充分利用部分閒置土地、廠房、設備及設施,通過優化配置,利用新技術、新工藝,建設一條新的牛磺酸生產線,形成年產4萬噸牛磺酸食品添加劑的生產能力。
項目計劃投資2.5億元人民幣,所需資金為公司自有資金。項目達產後,預計年均可實現銷售收入8.4億元(含税),税前利潤總額約1.48億元。
該項目是為了擴大牛磺酸的生產能力、增加市場份額,更好的滿足牛磺酸市場需求增長的需要。項目完成後,公司將具備年產近10萬噸牛磺酸生產能力,進一步鞏固全球最大牛磺酸生產基地地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.